Recent studies have focused on the intersection of GLP-1|GIP|GCGR agonist therapies and dopaminergic signaling. While GLP stimulators are increasingly employed for treating type 2 T2DM, their unexpected impacts on https://jaykahf953556.blog-ezine.com/41555650/new-glp-agonists-and-dopaminergic-modulation-a-comparative-assessment